Navigation Links
Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors
Date:6/16/2011

LOS ANGELES (June 15, 2011) An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.

Patients with newly diagnosed glioblastoma multiforme, the most common and aggressive type of tumor originating in the brain, typically live only 12 to 15 months after diagnosis even with standard treatments: surgery, radiation and chemotherapy.

In this Phase I clinical trial that started in November 2006, 11 of 16 patients (69 percent) were still alive at 32 months (a median analysis time); six of 16 (38 percent) continued to be disease-free; three have gone almost four years and another three have survived more than 2.5 years with no recurrence. Median progression-free survival the time from treatment to disease recurrence (median progression-free survival) was 16.9 months.

Phase I trials generally address dosage and safety issues. To further evaluate survival statistics, a randomized, multicenter, placebo-controlled Phase II trial has been launched.

ICT-107 targets six antigens found on glioblastoma cells, three of which also are found on cancer stem cells. Those cells widely are believed to be the original source of tumor cells, enabling them to resist treatment and recur. The study revealed that all 16 patients had at least three of the targeted antigens and 75 percent had all six. Patients who had four of the antigens (MAGE-A1, AIM2, gp100 and HER2) had better immune responses and longer progression-free survival rates.

Surasak Phuphanich, MD, director of the Neuro-Oncology Program of the Department of Neurosurgery and the Department of Neurology at Cedars-Sinai, termed another finding significant: levels of a protein associated with cancer stem cells (CD133) decreased in patients who had tumor recurrence after vaccination.

"Previous studies showed an increase in CD133 expression in patients who underwent treatment with radiation and chemotherapy. Our findings suggest that targeting antigens that are highly expressed by cancer stem cells may be a viable strategy for treating patients who have glioblastoma," he said.

Phuphanich participated in other multicenter studies that were presented at the ASCO meetings, including:

  • "A phase II study of verubulin (MPC-6827) for treatment of subjects with recurrent glioblastoma nave to treatment with bevacizumab," a poster presentation beginning at 8 a.m. on June 4.

  • "A phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma," a poster presentation beginning at 8 a.m. on June 4.

  • "A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma," an oral platform presentation beginning at 8 a.m. on June 5.

ICT-107 is a product of the biotechnology company ImmunoCellular Therapeutics, Ltd. Keith L. Black, MD, chairman of Cedars-Sinai's Department of Neurosurgery, director of the Maxine Dunitz Neurosurgical Institute and director of the Johnnie L. Cochran, Jr. Brain Tumor Center, is chairman of the company's scientific advisory board. John S. Yu, MD, vice chairman of Neurosurgery, director of the Brain Tumor Center of Excellence, director of Surgical Neuro-Oncology and surgical director of the Gamma Knife Center at Cedars-Sinai, is chief scientific officer, chairman of the board, and shareholder of ImmunoCellular. Certain rights in the dendritic cell vaccine technology and corresponding intellectual property have been exclusively licensed by Cedars-Sinai to ImmunoCellular Therapeutics, including subsequently developed versions of the vaccine investigated in this clinical study.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Rep. Giffords to Get Skull Patch in Latest Step in Recovery
2. Latest Artificial Pancreas Trials Reduce Risk of Low Blood Sugar
3. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
4. Latest findings of Dartmouth HIV/AIDS study could turn treatment on its head
5. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
6. Latest American Chemical Society podcast: Dont blame the pill for estrogen in drinking water
7. New works by UofL professors provide latest oncology reference guides
8. CTO summit and left main coronary interventions course will feature latest research and techniques
9. ASHs 52nd Annual Meeting and Exposition showcases the latest advances in the field
10. Latest American Chemical Society podcast: New water filter kills disease-causing bacteria
11. Latest Findings Back Mammograms for Women in Their 40s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet ... a conversation on the current obstacles facing infection prevention and offer strategies for ... caused by these infections. , The print component of “Fighting Infection” is ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Texas Physical ... can be found at 9618 Huebner Road. The clinic is the group’s 7th location ... Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which opened ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... ) announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center ... in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Appliances and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), ... Sunshine Heart Inc. (NASDAQ: SSH ). These companies ... of its prior gains on Thursday, March 23 rd , ... the afternoon, while shares of health care companies in the ...
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with 9,250 ... revealed that health plan members want help from their ... stay engaged in their health, 2) help closing gaps ... platform for health and 5) relevant, real-time guidance. Meeting ... lowering healthcare costs. A Reason ...
(Date:3/24/2017)... The Board of Directors of Nordic ... 2016 including the complete 2016 Annual Accounts with notes. The ... Nanovector,s website in the section Investor Relations/Reports and presentations/Annual Reports. ... For ... Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: